Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MicroPort CardioFlow Medtech Corporation (2160.HK)
HKD1.16
+0.03 (+2.65%)
CN HKSE Healthcare Medical - Devices
Address
Zhangjiang Hi-Tech Park 201203
Shanghai, CN
Shanghai, CN
CEO
Ruinian Zhang
Website
cardioflowmedtech.com
IPO
2021-02-04
ISIN KYG6082P1211
Description
MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD1.16
+0.03 (+2.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.28
Float Shares
227.22M
Free Float %
46.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.78% | -11.70% | -30.83% | -52.84% | -71.86% | -72.56% | -61.40% | -81.14% | -98.15% | -98.24% | -98.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.16
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.59
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+10.3% Q4'25: +6.6% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-155.9% Q4'25: -123.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-34.9% Q4'25: -22.5% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-34.5% Q4'25: -47.5% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%— Q4'25: +43.0% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+5.2% Q4'25: -79.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-2.32× Q4'25: 12.75× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
103.93M
est: 129.74M (-19.9%)
|
200.81M
est: 281.77M (-28.7%)
|
251.03M
est: 312.67M (-19.7%)
|
336.22M
est: 356.18M (-5.6%)
|
361.57M
est: 455.40M (-20.6%)
|
398.91M
est: 464.49M (-14.1%)
|
311.27M
311.27M – 311.27M
-33.0% YoY
|
337.73M
337.73M – 337.73M
+8.5% YoY
|
817.61M
817.61M – 817.61M
+142.1% YoY
|
| EBITDA |
-227.43M
est: -108.46M (-109.7%)
|
-173.99M
est: -235.55M (+26.1%)
|
-347.91M
est: -261.38M (-33.1%)
|
-386.05M
est: -244.43M (-57.9%)
|
-113.32M
est: -312.52M (+63.7%)
|
-100.29M
est: -318.75M (+68.5%)
|
-213.61M
-213.61M – -213.61M
+33.0% YoY
|
-231.77M
-231.77M – -231.77M
-8.5% YoY
|
-561.09M
-561.09M – -561.09M
-142.1% YoY
|
| EBIT |
-251.94M
est: -110.97M (-127.0%)
|
-179.82M
est: -241.01M (+25.4%)
|
-365.84M
est: -267.44M (-36.8%)
|
-459.67M
est: -258.01M (-78.2%)
|
-137.87M
est: -329.88M (+58.2%)
|
-137.67M
est: -336.46M (+59.1%)
|
-225.47M
-225.47M – -225.47M
+33.0% YoY
|
-244.64M
-244.64M – -244.64M
-8.5% YoY
|
-592.26M
-592.26M – -592.26M
-142.1% YoY
|
| Net Income |
-398.09M
est: -255.08M (-56.1%)
|
-183.26M
est: -154.57M (-18.6%)
|
-454.40M
est: -211.48M (-114.9%)
|
-471.53M
est: -67.73M (-596.2%)
|
-49.45M
est: -147.58M (+66.5%)
|
-131.60M
est: -52.32M (-151.6%)
|
-6.83M
-6.83M – -6.83M
+87.0% YoY
|
-2.29M
-2.29M – -2.29M
+66.5% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
150.30M
est: 120.55M (+24.7%)
|
157.66M
est: 261.81M (-39.8%)
|
232.77M
est: 290.52M (-19.9%)
|
293.23M
est: 275.34M (+6.5%)
|
222.44M
est: 352.04M (-36.8%)
|
265.45M
est: 359.06M (-26.1%)
|
240.62M
240.62M – 240.62M
-33.0% YoY
|
261.07M
261.07M – 261.07M
+8.5% YoY
|
632.04M
632.04M – 632.04M
+142.1% YoY
|
| EPS |
-0.85
est: -0.11 (-679.4%)
|
-0.39
est: -0.07 (-494.7%)
|
-0.95
est: -0.09 (-950.6%)
|
-1.00
est: -0.14 (-626.6%)
|
-0.11
est: -0.30 (+64.8%)
|
-0.27
est: -0.11 (-154.0%)
|
-0.01
-0.01 – -0.01
+87.0% YoY
|
0.00
0.00 – 0.00
+66.5% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-136.98M
OE per share TTM
-0.29
Owner's Yield
-83.84%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
122.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.00% | 14.5K | 0.65% |
| 2 | State Street SPDR S&P China ETF GXC | 0.00% | 1.4K | 0.59% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-320.2K
Shares Outstanding
491.76M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ruinian Zhang | CEO, GM & Executive Director | 2M | male |
| Philippe Wanstok | President & Executive Director | 156.7K | male |
| Paul Vodden | Chief Financial Officer | — | male |
| Alice Flacco | Executive VP & General Counsel | — | female |
| Lok Yee Chan | Joint Company Secretary | — | female |
| Xiangmei Li | Joint Company Secretary | — | female |
| Xiaoming Zhu | Chief Operating Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2160.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
